en
Scientific article
English

Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children

Published inJournal of medical economics, vol. 15, no. 2, p. 378-393
Publication date2012
Abstract

A pharmacoeconomic analysis was undertaken to determine costs, consequences, and cost-effectiveness of a partially hydrolyzed 100% whey-based infant formula, NAN-HA®, manufactured by Nestlé S.A, Switzerland (PHF-W), branded under BEBA HA® in Switzerland, in the prevention of atopic dermatitis (AD) in 'at risk' Swiss children when compared to standard cow's milk formula (SF).

Keywords
  • Child, Preschool
  • Cost-Benefit Analysis
  • Dermatitis, Atopic/economics/prevention & control
  • Dietary Proteins
  • Economics, Pharmaceutical
  • Health Resources/economics/utilization
  • Humans
  • Infant
  • Infant Formula/chemistry/economics
  • Milk Hypersensitivity
  • Milk Proteins
  • Models, Economic
  • Outcome Assessment (Health Care)
  • Sensitivity and Specificity
  • Switzerland
Citation (ISO format)
ISKEDJIAN, Michael et al. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children. In: Journal of medical economics, 2012, vol. 15, n° 2, p. 378–393. doi: 10.3111/13696998.2011.650521
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1369-6998
524views
0downloads

Technical informations

Creation10/14/2013 1:57:00 PM
First validation10/14/2013 1:57:00 PM
Update time03/14/2023 8:40:16 PM
Status update03/14/2023 8:40:16 PM
Last indexation01/16/2024 8:20:51 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack